{"id":2435,"date":"2026-08-05T08:00:00","date_gmt":"2026-08-05T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2435"},"modified":"2026-08-05T20:11:20","modified_gmt":"2026-08-06T00:11:20","slug":"damora-therapeutics-opens-mutant-calr-trial","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2435","title":{"rendered":"Damora Therapeutics Opens Mutant-CALR Trial"},"content":{"rendered":"

Company:<\/strong> Damora Therapeutics · Event Type:<\/strong> Pivotal Trial Initiation (Phase 1\/1b) · Modality:<\/strong> Fc-Null Monoclonal Antibody · Asset:<\/strong> DMR-001 · Indication:<\/strong> Mutant-CALR Essential Thrombocythemia \/ Myelofibrosis<\/p>\n

\"Damora<\/p>\n

Summary<\/h4>\n

Damora Therapeutics initiated CLARITY-101, a global Phase 1\/1b trial of DMR-001 in adults with mutant-calreticulin-driven essential thrombocythemia or myelofibrosis. DMR-001 is an Fc-null monoclonal antibody designed to bind Type 1 and non-Type 1 mutant CALR, block the pathogenic mutant-CALR–MPL interaction and permit once-monthly subcutaneous dosing.<\/p>\n

The transition into human testing is a material hematology signal because it tests direct inhibition of a clonal driver shared across a substantial subset of myeloproliferative neoplasms. It is not efficacy evidence. Disease modification, mutant-clone reduction, marrow-fibrosis reversal, thrombosis benefit and normal-hematopoiesis safety remain unproven.<\/p>\n

What Happened<\/h4>\n

Damora announced trial initiation on August 5, 2026, at 8:00 a.m. ET after receiving health-authority approval.<\/p>\n

CLARITY-101 is an open-label, multicenter dose-escalation and expansion study. Phase 1 begins with 100 mg subcutaneous DMR-001 every four weeks and uses an adaptive Bayesian design to identify a recommended Phase 1b dose. Eligible patients include adults with documented CALR mutations and either essential thrombocythemia that is resistant, refractory or intolerant to at least one cytoreductive therapy, or myelofibrosis that is resistant, refractory or intolerant to at least one JAK inhibitor. Later expansion is planned in earlier-line and combination settings.<\/p>\n

Damora expects initial clinical data beginning in mid-2027. The public release did not provide a clinical-trial registration number, target enrollment, dose-escalation ceiling, dose-limiting-toxicity window, statistical expansion thresholds or jurisdiction-specific approval details.<\/p>\n

Mechanistic Rationale<\/h4>\n

Mutant CALR gains an aberrant positively charged C-terminus that binds and activates the thrombopoietin receptor MPL, driving JAK–STAT signaling and clonal proliferation. A mutation-selective antibody could suppress this upstream driver while sparing wild-type CALR, potentially avoiding the broad myelosuppression of nonspecific pathway inhibition. DMR-001’s Fc-null design is intended to minimize Fc-mediated effector activity; YTE engineering is intended to extend serum half-life.<\/p>\n

Preclinical Differentiation<\/h4>\n

Damora reports activity against both Type 1 and Type 2-like mutant CALR variants, up to approximately 30-fold greater binding affinity and up to 26-fold greater potency than a reference antibody in selected assays, plus an approximately 15-day nonhuman-primate half-life versus 3.1 days for the reference. These are company-generated comparator claims. They do not establish human target occupancy, marrow penetration, pharmacodynamic depth or superiority over other mutant-CALR antibodies.<\/p>\n

Translational Constraints<\/h4>\n

Soluble and cell-associated mutant CALR, variable mutation burden, marrow architecture and competing subclones may affect exposure and response. Monthly subcutaneous delivery is operationally attractive only if concentrations remain above the biologically active threshold throughout the interval. Safety must distinguish intended clone suppression from impaired platelet production, cytopenias, immunogenicity and effects on normal hematopoietic stem and progenitor cells.<\/p>\n

Reading the Signal<\/h4>\n

One plausible reading is that DMR-001 could become a genotype-defined disease-modifying therapy by shutting off a causal extracellular driver upstream of JAK–STAT signaling. Supporting evidence includes mutation selectivity, coverage of major CALR classes, preclinical pathway blockade and clinical entry. Contradicting evidence is the absence of human pharmacology, allele-burden reduction, histologic improvement or clinical outcomes.<\/p>\n

A second plausible reading is that the trial validates a tractable antibody approach without yet demonstrating enough tissue exposure or pathway suppression to change disease biology. Supporting evidence includes the early-stage design and reliance on preclinical comparisons. Against that interpretation, mutant CALR is extracellularly accessible and genetically central in the selected population, which provides a cleaner target-validation basis than many downstream signaling targets.<\/p>\n

The interpretation would be upgraded by dose-proportional exposure, sustained target engagement, suppression of MPL–STAT signaling, consistent activity across CALR subtypes, reduced mutant allele burden, durable hematologic responses and improved marrow fibrosis without material cytopenias or immunogenicity. It would be downgraded by rapid target-mediated clearance, weak marrow pharmacodynamics, subtype-restricted activity or cumulative hematologic toxicity. Failure to produce biological target engagement at tolerated exposure would falsify the current mechanism-to-clinic thesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • New event:<\/strong> Global Phase 1\/1b CLARITY-101 initiated after health-authority approval.<\/li>\n
  • Population:<\/strong> Mutant-CALR essential thrombocythemia and myelofibrosis after prior standard therapy.<\/li>\n
  • Mechanism:<\/strong> Mutation-selective Fc-null antibody blockade of mutant CALR interaction with MPL.<\/li>\n
  • First disclosed regimen:<\/strong> 100 mg subcutaneously every four weeks; adaptive Bayesian escalation.<\/li>\n
  • Next catalyst:<\/strong> Initial clinical data expected beginning mid-2027.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a 4\/5 positive\/uncertain signal. Clinical entry materially advances a biologically specific hematology program with a credible route to clonal-driver inhibition. The directional claim stops at development progress: no patient pharmacology, efficacy, safety or disease-modification evidence is available, and preclinical potency comparisons may not predict clinical differentiation.<\/p>\n

    Company and Product Background<\/h4>\n

    Damora Therapeutics develops medicines for blood disorders and became a public company following Galecto’s acquisition of Damora in 2025. DMR-001 is its lead anti-mutant-CALR antibody. Damora states that approximately 25% of essential-thrombocythemia cases and 35% of myelofibrosis cases are driven by CALR mutations and that no approved therapy directly targets mutant CALR.<\/p>\n

    Essential thrombocythemia and myelofibrosis are chronic myeloproliferative neoplasms arising from clonal hematopoietic stem and progenitor cells. ET creates thrombotic and bleeding risk through abnormal megakaryopoiesis and platelet production. MF causes marrow fibrosis, splenomegaly, constitutional symptoms, cytopenias and risk of acute myeloid leukemia transformation. Current therapies can control counts or symptoms but do not consistently eradicate the founding clone.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4\/5. Signal Direction: positive\/uncertain. Confidence in Facts: high for trial initiation, mechanism and disclosed design; medium for preclinical comparative claims. Confidence in Interpretation: medium — the mechanistic thesis is strong but human translation is untested.<\/p>\n

    Missing facts include the registry identifier, enrollment target, complete escalation schema, pharmacodynamic thresholds, jurisdiction details and independent validation of comparator claims.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Damora Therapeutics initiated CLARITY-101, a global Phase 1\/1b trial of DMR-001 in adults with mutant-calreticulin-driven essential thrombocythemia or myelofibrosis. DMR-001 is an Fc-null monoclonal antibody designed to bind Type 1 and non-Type 1 mutant…<\/p>\n","protected":false},"author":1,"featured_media":2443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[285,286,115],"class_list":["post-2435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-damora-therapeutics","tag-monoclonal-antibody","tag-myeloproliferative-neoplasms"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2435"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2435\/revisions"}],"predecessor-version":[{"id":2450,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2435\/revisions\/2450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2443"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}